Add this topic to your myFT Digest for news straight to your inbox
Impax sells course of treatment for $880, against £3.50 for British equivalent
Pharmaceutical group accused of paying $112m to stall introduction of generic rival
Valeant and Allergan chiefs signal end to ‘buy and raise’ deals
US stocks rally strongly in early trading on debt talks hopes
International Edition